Founder and CEO

Chief Medical Officer

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics?

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Medical Science Liaison

Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. The Medical Science Liaison (MSL) will develop relationships with medical thought leaders in the metabolic and oncologic space, providing scientific support and medical information to enhance the company's mission of delivering hope to patients with rare diseases.

Sign up with Google

Sign in with Google